Werewolf Therapeutics, Inc. (HOWL)
NASDAQ: HOWL · Real-Time Price · USD
1.600
-0.070 (-4.19%)
At close: Oct 17, 2025, 4:00 PM EDT
1.620
+0.020 (1.25%)
After-hours: Oct 17, 2025, 7:55 PM EDT
Werewolf Therapeutics Revenue
In the year 2024, Werewolf Therapeutics had annual revenue of $1.89M, down -90.55%.
Revenue (ttm)
$1.89M
Revenue Growth
-90.55%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
46
Market Cap
73.17M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.89M | -18.06M | -90.55% |
| Dec 31, 2023 | 19.94M | 3.54M | 21.60% |
| Dec 31, 2022 | 16.40M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
HOWL News
- 10 days ago - Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer - GlobeNewsWire
- 15 days ago - Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting - GlobeNewsWire
- 6 weeks ago - Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit - GlobeNewsWire
- 4 months ago - Werewolf Therapeutics to Participate in the BIO International Convention - GlobeNewsWire
- 5 months ago - Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 months ago - HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124 - GlobeNewsWire